Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary efficacy endpoint in preventing COVID-19. Key highlights from the announcement were as follows: Two different dosing regimens demonstrated efficacy with… Read More
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, with effect from 1 December 2020, Dr. Siyamak (“Sam”) Rasty has been appointed to the Group’s Board as a Non-Executive Director. Dr. Rasty… Read More
Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability PhoreMost’s SITESEEKER platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector® delivery system Oxford, UK – 9 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group… Read More
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant Gene Therapies’ (“Axovant”) positive six-month follow-up data from the second cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease. Key highlights… Read More
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the Group’s… Read More
Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2020. FINANCIAL HIGHLIGHTS • Revenue increased by 6% to £34.0 million (H1 2019: £32.1 million) Continued… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public… Read More
Oxford, UK – 27 August, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2020 on Thursday 17 September 2020. A virtual briefing and Q&A… Read More
Oxford, UK – 3 August 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture & License Agreement (“DMLA”) with Beam Therapeutics Inc. (“Beam”) (Nasdaq: BEAM), a Cambridge, Mass.-based biotechnology company developing precision… Read More
Oxford, UK – 31st July, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a three year Clinical Supply Agreement (“CSA”) with a wholly-owned subsidiary of Axovant Gene Therapies Ltd. (“Axovant”) (Nasdaq: AXGT). The CSA builds… Read More
Oxford, UK – 20 July, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd (“AstraZeneca”) has announced interim results from the ongoing Phase I/II COV001 trial, led by Oxford University on AZD1222 which showed the SARS-CoV-2 vaccine… Read More
Annual General Meeting Held at the offices of Oxford Biomedica at Windrush Court, Transport Way, Oxford OX4 6LT on 23 June 2020 at 3.00 p.m. Any questions emailed to us are outlined below Q What was the process of selecting Dr Roch Doliveux as the new ChairmanA. … Read More